Royalty Pharma (RPRX) Stock Forecast & Price Target

$24.47 -0.65 (-2.59%)

(As of 12/18/2024 05:44 PM ET)

Royalty Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Royalty Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for RPRX.

Consensus Price Target

$41.67
70.28% Upside

According to the 6 analysts' twelve-month price targets for Royalty Pharma, the average price target is $41.67. The highest price target for RPRX is $51.00, while the lowest price target for RPRX is $28.00. The average price target represents a forecasted upside of 70.28% from the current price of $24.47.

Get the Latest News and Ratings for RPRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Royalty Pharma and its competitors.

RPRX Analyst Ratings Over Time

Type	Current Forecast 12/20/23 to 12/19/24	1 Month Ago 11/20/23 to 11/19/24	3 Months Ago 9/21/23 to 9/20/24	1 Year Ago 12/20/22 to 12/20/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$41.67	$41.67	$42.00	$55.00
Forecasted Upside	70.28% Upside	60.19% Upside	52.51% Upside	103.18% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

This Crypto Is Set to Explode in December (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

RPRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RPRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Royalty Pharma Stock vs. The Competition

Type	Royalty Pharma	Finance Companies	S&P 500
Consensus Rating Score	2.83	2.49	2.51
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	70.28% Upside	18.32% Upside	15.36% Upside
News Sentiment Rating	Positive News See Recent RPRX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/25/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$60.00 ➝ $40.00	+47.17%
8/14/2024	The Goldman Sachs Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$50.00 ➝ $51.00	+89.87%
7/11/2024	Morgan Stanley 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$48.00 ➝ $51.00	+90.65%
6/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$28.00	+2.83%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$40.00 ➝ $38.00	+30.81%
2/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$45.00 ➝ $42.00	+39.21%
4/6/2023	Tigress Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$57.00 ➝ $60.00	+64.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:49 AM ET.

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com.

Royalty Pharma
Bull Case

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

The current stock price is $26.43, which is relatively stable compared to its fifty-two week high of $31.66, indicating potential for growth as it approaches previous highs.
Royalty Pharma plc has a strong market capitalization of approximately $15.57 billion, suggesting a solid position in the biopharmaceutical industry, which can attract institutional investors.
The company has announced a quarterly dividend of $0.21 per share, translating to an annualized dividend of $0.84 and a yield of 3.18%, providing a steady income stream for investors.
With institutional investors owning 54.35% of the company's stock, there is a level of confidence from large financial entities, which can be a positive indicator for potential investors.
The average rating for Royalty Pharma plc is "Moderate Buy" with a price target of $41.67, suggesting that analysts see significant upside potential in the stock price.

Royalty Pharma
Bear Case

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

The stock has a relatively low beta of 0.47, indicating lower volatility compared to the market, which may limit potential high returns during bullish market conditions.
The price-to-earnings (P/E) ratio is 13.69, which, while not excessively high, may suggest that the stock is fairly valued, leaving less room for significant price appreciation.
The P/E/G ratio of 4.64 indicates that the stock may be overvalued relative to its earnings growth rate, which could deter growth-focused investors.
Royalty Pharma plc's debt-to-equity ratio of 0.64 suggests a moderate level of debt, which could pose risks if the company faces financial challenges or market downturns.
Recent trading volumes have been below average, which may indicate a lack of investor interest or confidence in the stock at its current price levels.

RPRX Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Royalty Pharma is $41.67, with a high forecast of $51.00 and a low forecast of $28.00.
: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RPRX shares.
: According to analysts, Royalty Pharma's stock has a predicted upside of 70.28% based on their 12-month stock forecasts.
: Royalty Pharma has been rated by research analysts at Citigroup in the past 90 days.
: Analysts like Royalty Pharma more than other "finance" companies. The consensus rating for Royalty Pharma is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how RPRX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Crypto Is Set to Explode in December (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

This page (NASDAQ:RPRX) was last updated on 12/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Stock Forecast & Price Target